HUYABIO International, LLC

HUYABIO International, LLC describes itself as the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China, enabling faster, more cost-effective and lower-risk drug development in global markets. Through collaboration with biopharmaceutical, academic and commercial organizations, it states it has built the largest China-sourced compound portfolio covering all therapeutic areas. The company reports offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, and describes itself as a partner of choice to accelerate product development and maximize value globally.

HUYABIO International describes its foundation in the momentum of innovative life-sciences R&D in the East, with China leading the charge. Its Chief Executive Officer and Executive Chair, Mireille Gillings, PhD, Hon DSc, states that she wanted to identify and add value to therapeutic opportunities from Chinese institutes and universities, and that HUYABIO has grown to be the leader in globalizing China's pharmaceutical innovation. The company reports teams in San Diego, Tokyo, Dublin, Montreal, Seoul and eight China offices, and describes diverse approaches including in-licensing, alliances, co-development, research funding and creative financial partnerships.

Leader in globalizing China's biopharma innovation; partner of choice to accelerate product development and maximize value globally.

1. 1The Leader in Globalizing China’s Biopharma Innovation - HUYABIO Internationalhuyabio.com
2. 2Management - HUYABIO Internationalhuyabio.com
3. 3Welcome from the Chief Executive Officer and Executive Chair - HUYABIO Internationalhuyabio.com
4. 4Cardiovascular Scientific Advisory Board - HUYABIO Internationalhuyabio.com